Capsida Biotherapeutics to Attend Investor and Industry Conferences on IND-enabling Studies Progress

Capsida Biotherapeutics, a prominent gene therapy company based in Thousand Oaks, California, has announced its participation in several investor and industry conferences this September and October. The focus will be on the company’s progress with its proprietary intravenous (IV) administered treatments: CAP-002 targeting genetic epilepsy due to STXBP1 mutations and CAP-003 aimed at Parkinson's disease linked to GBA mutations. Both of these programs are poised to enter clinical trials in the first half of 2025. 

Capsida Biotherapeutics specializes in developing gene therapies for diseases affecting the central nervous system (CNS), targeting both rare and common conditions across different age groups. Their gene therapies are delivered intravenously using proprietary engineered capsids, which achieve high transduction levels in the desired tissues and cells while minimizing effects on non-target organs such as the liver.

The company’s pipeline includes three wholly owned programs. Among these, CAP-002 and CAP-003 stand out as potential best-in-class treatments for genetic epilepsy due to STXBP1 mutations and Parkinson's disease associated with GBA mutations. Both programs are currently in IND-enabling studies and are expected to commence clinical trials in the first half of 2025.

Capsida also collaborates with industry leaders to enhance its CNS-focused research. Notable partnerships include those with AbbVie, Lilly, and CRISPR Therapeutics. The collaboration with AbbVie has even been expanded to cover ophthalmology disorders, showcasing the flexibility and potential of Capsida's platform.

Founded in 2019, Capsida emerged from cutting-edge research conducted in the laboratory of Dr. Viviana Gradinaru, a neuroscience professor at Caltech. Versant Ventures and Westlake Village BioPartners were the lead investors that supported Capsida's inception. The company has since grown to become a fully integrated entity, leveraging its unique capsid engineering to develop innovative gene therapies for CNS diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!